Hector Alila, D.V.M., Ph.D.
President and Chief Executive Officer
Dr. Alila is the founding President and Chief Executive Officer of Esperance. He has more than 28 years of senior management experience in drug development in large pharmaceutical and biotech companies and academic research experience. Prior to joining Esperance Dr. Alila served as Senior Vice President of Drug Development at Protalex, Inc. in New Hope, PA, Vice President of Product Development at Cell Pathways, Inc. in Horsham, PA, (later acquired by OSI Pharmaceuticals, which was acquired by Astellas Pharma Inc.), Director of Biology/Pharmacology at GeneMedicine, Inc. in The Woodlands, TX, (which merged with Megabios to become Valentis, Inc.) and several research, development, and management positions at SmithKline Beecham (now GlaxoSmithKline) in Pennsylvania. He obtained his veterinary degree from the University of Nairobi (Kenya) and continued his training at University of Pennsylvania to become a licensed veterinarian to practice in Pennsylvania and New York.
Dr. Alila obtained his Ph.D. in physiology and immunology from Cornell University (Ithaca, NY) where he also held a faculty position as Senior Research Associate in Physiology at the Veterinary College. Dr. Alila has published over 40 scientific papers in peer-reviewed journals, two book chapters and holds 12 issued patents. He serves on the boards of several companies, state and philanthropic organizations. He is a recipient of several awards for his pioneering work in reproduction, anti-infective agents, autoimmune diseases and cancer.
Carola Leuschner, Dr. rer. Nat., Ph.D.
Vice President of Research and Development
Dr. Leuschner has served as Vice President of Research since 2015 when she was promoted from Senior Director of Biology, a role Dr. Leuschner held since 2007. During her career, Dr. Leuschner’s research has focused on the development of anti-cancer drugs and imaging systems for non-invasive cancer detection in applications for prostate, breast, and ovarian cancers as Associate Professor in the Department of Reproductive Biotechnology at Pennington Biomedical Research Center (PBRC) in Baton Rouge, Louisiana. She also served as an Instructor in the Department of Diet and Heart Disease at the Pennington Biomedical Center.
Dr. Leuschner obtained her doctorate degree in Biochemistry at the University of Hannover, Germany with postdoctoral training at the Department of Technical Microbiology of Hamburg University, Germany. She has published two book chapters, over 40 peer reviewed articles and holds several patents (3 patents issued on Esperances technology). Dr. Leuschner is the recipient of the Nano50 2006 Technology Award an award that recognized the 50 best innovations in nanotechnology. Dr. Leuschner received this award on studies on nanoparticles for metastases detection and treatment.
Clarice Motter, CPA, CGMA
Interim Chief Financial Officer and Controller
Ms. Motter serves as Interim Chief Financial Officer and Controller. She hold an Masters in Business Administration from UCLA and is a licensed CPA and CGMA with more than 30 years experience as an accounting professional. She worked as an Auditor with KPMG prior to entering the private sector. Her expertise in a variety of industries includes the establishment and management of all accounting, finance, treasury, budget, tax, credit, human resources, and administration functions in both start up and existing operations.
Ms. Motter’s focus has been life science startups and has been involved with companies in all stages of development, including founding, early-stage, pre-IPO, IPO, follow-on and M&A activities. She works closely with CEO’s to negotiate private investments and establish strategic plans for growth and development. She has also worked with her clients to manage non-dilutive financing including grant budgeting, accounting and administration. She has been the CFO for many life science companies including: Beta Cat, Kiromic, Salerius Pharmaceuticals, Vapogenix Inc., Nano3D Biosciences, CorInnova, LifeCell, Repros, Chrysalis, ProlX, Aronex, RGene Therapeutics, OrthoAccel, and Avisa.